DiaMedica Therapeutics logo
DiaMedica Therapeutics
DMAC | NASDAQ
Chart Builder DCF Calculator
$8.33
-$0.46 (-5.23%)
At close: Nov 16, 2026, 4:00 PM ET
$8.33
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

DiaMedica Therapeutics Company Profile

Company profile explained

Company Profile

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Key Executives

Name Position
Dietrich John Pauls President, Chief Executive Officer & Director
Ambarish Shah Chief Technology Officer
Scott Kellen Chief Financial Officer & Corporate Secretary
Dominic R. Cundari Chief Commercial Officer
Julie Krop Chief Medical Officer

Latest SEC Filings

Date Type Title
Aug 12, 2026 4 Filing
Aug 11, 2026 S-8 Filing
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Jun 03, 2026 4 Filing
Jun 03, 2026 4 Filing
Jun 03, 2026 4 Filing
Jun 03, 2026 4 Filing
Jun 03, 2026 4 Filing
Jun 03, 2026 4 Filing
View All SEC Filings ➞
DiaMedica Therapeutics
DiaMedica Therapeutics logo
Country United States
IPO Date Aug 3, 2012
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Dietrich John Pauls

Contact Details

Two Carlson Parkway Minneapolis, Minnesota 55305 United States

Stock Details

Ticker Symbol DMAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401040
CUSIP Number 25253X207
ISIN Number CA25253X2077
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.